Novo Nordisk To Start Phase III Trials Of Hemophilia Contender Concizumab In 2H
Subcutaneous bypassing agent concizumab will progress to Phase III after positive late-stage trials shows promise for all patients with hemophilia.
Subcutaneous bypassing agent concizumab will progress to Phase III after positive late-stage trials shows promise for all patients with hemophilia.